<DOC>
	<DOC>NCT03059511</DOC>
	<brief_summary>To assess pharmacokinetics parameters for nalbuphine after intravenous and intranasal administration in infants. Also effect on pain score: Neonatal Infant Pain Score (NIPS) and safety will be evaluated with summary of Adverse Events. Inclusion criteria are: Infants 29 days-3 months, minimum Body weight 3.0 kg, Indications: septical work up. Exclusion criteria are: Infants who were born prematurely (before 37 weeks gestation), known kidney or liver disease, known chronic illness.</brief_summary>
	<brief_title>Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants</brief_title>
	<detailed_description />
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Infants 29 days3 months Minimum Body weight 3.0 kg Indications: septical work up Parent has been informed about the study and has signed Informed Consent Form Infants who were born prematurely (before 37 weeks gestation) Known kidney or liver disease Known chronic illness Documented previous adverse reaction to nalbuphine Treatment with a depressant drug within 5 days prior to study Epistaxis, nose trauma (only for the intranasal application) Barriere of language</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>